BioCentury
ARTICLE | Strategy

Growing up Genzyme

How Bioverativ solidifies Genzyme as Sanofi’s growth engine

January 27, 2018 1:40 AM UTC

The proposed acquisition of Bioverativ Inc. ticks multiple boxes on Sanofi’s to-do list for transforming itself into a top tier pharma, and solidifies the position of its Genzyme unit as the pharma’s growth engine.

Olivier Brandicourt became Sanofi’s CEO in April 2015 after Christopher Viehbacher’s ouster in the wake of flagging diabetes sales and moribund EPS performance. By August that year, the new CEO had outlined his plan to return the company to growth by 2020: get to and maintain positive EPS, replace declining Lantus insulin glargine revenues, and focus the company on disease areas and businesses where it could be a top-three company...